"Thiohydantoins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D013867
|
| MeSH Number(s) |
D03.383.129.308.432.555.868
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Thiohydantoins".
Below are MeSH descriptors whose meaning is more specific than "Thiohydantoins".
This graph shows the total number of publications written about "Thiohydantoins" by people in this website by year, and whether "Thiohydantoins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 1 | 0 | 1 |
| 2024 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Thiohydantoins" by people in Profiles.
-
Trends in novel antiandrogen receptor signal inhibitor use and medical costs in prostate cancer. Cancer Med. 2024 Dec; 13(24):e70226.
-
A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2024 Jul 01; 30(13):2751-2763.
-
A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlates. BJU Int. 2024 Sep; 134(3):449-458.
-
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study. Lancet Oncol. 2021 11; 22(11):1541-1559.
-
An evaluation of apalutamide for the treatment of prostate cancer. Expert Opin Pharmacother. 2020 Sep; 21(13):1537-1546.
-
Quality of life is not compromised with intensification of androgen therapy in recurrent prostate cancer. Lancet Oncol. 2018 10; 19(10):1275-1276.
-
Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases by 2-Thiohydantoin Compounds. J Med Chem. 2015 Sep 10; 58(17):6899-6908.
-
Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur Urol. 2015 Mar; 67(3):470-9.